Form 4: Repligen Corp Executive Ralf Kuriyel Reports Stock and Option Transactions

Senior VP of R&D at Repligen Corp, Ralf Kuriyel, reports acquisition of restricted stock units and stock options, along with a disposition of shares to cover tax obligations.

Summary

• On March 3, 2025, Ralf Kuriyel, Senior VP of R&D at Repligen Corp, acquired 4,826 shares of common stock through restricted stock units.
• These restricted stock units vest in equal annual installments over three years, starting on the first anniversary of the grant date.
• Kuriyel also acquired 4,542 stock options with an exercise price of $155.38, vesting annually from March 3, 2026, to March 3, 2028.
• Additionally, 386 shares of common stock were disposed of to cover tax withholding obligations at a price of $155.38 per share.
• Following these transactions, Kuriyel directly owns 16,062 shares of common stock and 4,542 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects standard insider transactions related to compensation. The acquisitions are a positive sign, but the tax-related disposal is a neutral event.

Positives

• The acquisition of restricted stock units and stock options suggests confidence in the company's future performance from an insider's perspective.

Negatives

• The disposal of 386 shares to cover tax obligations, while routine, slightly reduces Kuriyel's overall holdings.

Risks

• There are no specific risks explicitly mentioned in this document.
• However, insider transactions are always subject to scrutiny and potential misinterpretation by the market.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the restricted stock units and stock options extends to 2028 and 2035, respectively, indicating a long-term alignment of interests between the executive and the company.

Industry Context

Insider transactions are common in the biopharmaceutical industry, where stock options and restricted stock units are frequently used to incentivize and retain key personnel. These transactions are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants and restricted stock units are standard compensation practices in the biotech industry, comparable to companies like Amgen, Biogen, and Gilead Sciences.
• The vesting schedules and exercise prices are generally in line with industry norms for executive compensation packages.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by the executive.
• The transactions have no direct impact on employees, customers, suppliers, or creditors.

Key Dates